黄连饮片制剂的临床安全性研究

目的 对中药饮片制剂黄连的用量配伍及临床安全性进行研究，为临床用药提供参考依据。方法 对本院2014年8月至2016年7月使用黄连饮片的96例患者进行一般资料、用药情况、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、不良反应研究分析对比。结果 96例患者中，54例男性患者，42例女性患者，使用汤剂治疗71例（73.96%）、水丸治疗13例（13.54%）、颗粒治疗8例（8.33%）、粉剂治疗4例（4.17%）；男性患者的黄连日用量明显大于女性患者黄连日用量，差异具有统计学意义（P<0.05）；男性患者的疗程、黄连总用量显著低于女性患者的疗程、黄连总用量，差异均有统计学意义（P<0.05）。96例患者中共有5例患者出现ALT、AST变化，变化率为5.21%；7例出现不良反应，不良反应率为7.29%。结论 使用黄连饮片制剂进行疾病治疗，通常情况下不会出现过多的不良反应，但对于肝功能受损患者，在使用黄连饮片及配伍用药后，ALT、AST水平会出现一定程度升高，临床可据此进行配伍用药，以提高临床治疗的安全性。

Study on Clinical Safety of Rhizoma Coptidis Preparations

Objective To investigate the dosage compatibility and the clinical safety of rhizoma coptidis preparations and provide the reference for clinical medication. Methods The general information, medication situation, alanine aminotransferase (ALT) and aspartate amino transferase of 96 cases patients used rhizoma coptidis in our hospital from August 2014 to July 2016. were. Results Among 96 cases of patients, the number of male patients was 54, the number of female patients was 42. 71 cases of patients were treated with decoction therapy (73.96%), 13 cases of patients were treated with water pill therapy (13.54%), 8 cases of patients were treated with pellet therapy (8.33%), 4 cases of patients were treated with powder (4.17%). Male patients'' daily doses of rhizoma coptidis were obviously higher than that of female patients (P<0.05). Male patients'' course, total dosages of rhizoma coptidis were significantly lower than those of female patients (P<0.05). ALT and AST of 5 patients showed changes, the change rate was 7.29%. Adverse reactions happened in 7 cases of patientst the adverse reaction rate was 9.38%. Conclusion It will not show too many adverse reactions in the treatment of diseases with rhizoma coptidis preparations in general. But for the patients with impaired liver function, the level of ALT and AST will increase to some extent after taking of rhizoma coptidis and compatibility medications, which could improve the clinical safety of compatibility medications.